Dexcom Inc. reported its second-quarter 2024 financial results, showing a 15% year-over-year increase in revenue to $1.004 billion. Despite beating earnings per share (EPS) expectations with $0.43 compared to the estimated $0.39, the company missed revenue expectations of $1.1 billion. Dexcom's GAAP net income was $143.5 million, or $0.35 per diluted share, up from $115.9 million in the same quarter last year. The company also announced a $750 million share repurchase program. However, Dexcom lowered its full-year revenue guidance to a range of $4.00 billion to $4.05 billion, down from the previous estimate of $4.2 billion to $4.35 billion. This reduction in guidance, attributed to a restructuring of its sales team and fewer new customers, led to a significant drop in Dexcom's stock price, which fell as much as 40% in after-hours trading and 38% in premarket trading. The stock is now on pace for its worst day on record.